USFDA Guidance: Bioanalytical Method Validation for Biomarkers

The U.S. regulatory landscape continues to evolve to ensure data reliability and scientific rigor in drug development, particularly in the growing use of biomarkers. As biomarkers become increasingly critical for evaluating drug safety and efficacy, the FDA has issued specific guidance to standardize how bioanalytical methods for these measurements should be validated.

The guidance Bioanalytical Method Validation for Biomarkers was published in April 2026, providing recommendations for validating bioanalytical assays used to measure biomarker concentrations in drug and biologic development.

This guidance provides recommendations for sponsors and applicants on how to validate bioanalytical methods used to measure biomarker concentrations in biological samples such as blood and urine.

It applies to a wide range of regulatory submissions, including investigational new drug applications (INDs), new drug applications (NDAs), biologics license applications (BLAs), and abbreviated new drug applications (ANDAs).

The guidance focuses specifically on in vivo biomarker measurements and does not apply to veterinary drugs or veterinary biomarkers. It reflects the FDA’s current thinking and serves as a nonbinding recommendation for industry.

This guidance applies to the validation of bioanalytical assays used to measure biomarker concentrations in biological matrices during nonclinical and clinical studies. It supports drug development activities across different stages, including early research, clinical pharmacology, and pivotal trials.

The recommendations are relevant for assays used in regulatory submissions as well as those supporting internal decision-making within pharmaceutical development programmes. Bioanalytical Method Validation for Biomarkers

Biomarkers are widely used to assess the effects of drugs and biological products, making them essential tools in drug development. They support the evaluation of safety, efficacy, pharmacodynamics, and disease progression across both nonclinical and clinical studies.

Bioanalytical methods used to measure biomarkers must generate reliable and reproducible data, as these data often inform critical regulatory decisions. Therefore, appropriate validation of these methods is essential to ensure data integrity.

Fit-for-Purpose Approach

The FDA recommends a fit-for-purpose approach to method validation, where the extent of validation depends on how the biomarker data will be used.

When biomarker data are intended to support regulatory decision-making, such as demonstrating safety or efficacy or informing product labeling, the analytical method should be fully validated in accordance with ICH M10 principles.

In contrast, when biomarker assays are used for internal decision-making, such as candidate selection or proof-of-concept studies, the level of validation can be more flexible and determined by the sponsor.

Key Validation Considerations

Validation of bioanalytical methods for biomarkers focuses on ensuring that the method is reliable, accurate, and suitable for its intended purpose. Key considerations include whether the method specifically measures the intended analyte without interference and whether it demonstrates acceptable levels of accuracy and precision.

It is also important to establish the measurable range of the method, including sensitivity limits such as the lower and upper limits of quantitation. Additionally, factors such as sample collection, handling, storage conditions, and processing must be evaluated to ensure that they do not compromise data integrity.

These considerations collectively ensure that the method produces consistent and scientifically valid results.

Method Validation Parameters

Bioanalytical methods for biomarkers should be evaluated based on several critical performance characteristics. These include accuracy, precision, sensitivity, selectivity, reproducibility, and stability of the assay.

Additional parameters such as parallelism and assay range are also important, particularly for complex biomarker assays. These characteristics help define the reliability and robustness of the analytical method.

Alignment with ICH M10

The guidance emphasizes that the validation principles described in ICH M10 should serve as the starting point for biomarker assay validation. This includes approaches used for chromatography-based and ligand-binding assays.

However, the FDA acknowledges that certain validation criteria in ICH M10 may not be fully applicable to all biomarker assays, especially when using novel analytical platforms. In such cases, sponsors are encouraged to justify any deviations and discuss their approach with the FDA early in development.

References

For complete official guidance, refer to:

Bioanalytical Method Validation for Biomarkers – FDA Guidance